These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21176760)

  • 1. Safety review: squalene and thimerosal in vaccines.
    Montana M; Verhaeghe P; Ducros C; Terme T; Vanelle P; Rathelot P
    Therapie; 2010; 65(6):533-41. PubMed ID: 21176760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
    Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A
    Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of thimerosal in vaccines: for whom and how many doses?
    Dorea JG
    Therapie; 2011; 66(2):95-6. PubMed ID: 23189333
    [No Abstract]   [Full Text] [Related]  

  • 4. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review.
    Isai A; Durand J; Le Meur S; Hidalgo-Simon A; Kurz X
    Vaccine; 2012 Nov; 30(49):7123-9. PubMed ID: 23022149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.
    Pellegrini M; Nicolay U; Lindert K; Groth N; Della Cioppa G
    Vaccine; 2009 Nov; 27(49):6959-65. PubMed ID: 19751689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.
    Tsai T; Kyaw MH; Novicki D; Nacci P; Rai S; Clemens R
    Vaccine; 2010 Feb; 28(7):1877-80. PubMed ID: 19969117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study.
    Heikkinen T; Young J; van Beek E; Franke H; Verstraeten T; Weil JG; Della Cioppa G
    Am J Obstet Gynecol; 2012 Sep; 207(3):177.e1-8. PubMed ID: 22939717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
    J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Position of the Drug Committee of German Physicians on vaccination against the new influenza A (H1N1)].
    Kinderkrankenschwester; 2009 Nov; 28(11):463-5. PubMed ID: 19953852
    [No Abstract]   [Full Text] [Related]  

  • 11. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
    El Sahly H
    Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
    Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter to the editor. The safety of thimerosal in newborn and infant vaccines.
    Thompson WW; DeStefano F; Chen R
    Vaccine; 2004 Dec; 23(3):281-2. PubMed ID: 15530668
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of adjuvanted pandemic influenza A (H1N1) 2009 vaccines.
    DeStefano F; Vellozzi C; Schonberger LB; Chen RT
    BMJ; 2011 Jul; 343():d4159. PubMed ID: 21750073
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
    Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
    Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The history of MF59(®) adjuvant: a phoenix that arose from the ashes.
    O'Hagan DT; Ott GS; Nest GV; Rappuoli R; Giudice GD
    Expert Rev Vaccines; 2013 Jan; 12(1):13-30. PubMed ID: 23256736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
    Precioso AR; Miraglia JL; Campos LM; Goulart AC; Timenetsky Mdo C; Cardoso MR; Luna E; Mondini G; Guedes Jda S; Raw I
    Vaccine; 2011 Nov; 29(48):8974-81. PubMed ID: 21945258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.